Please select an option below to help us tailor your newsletter to best suit your content interests!
In a recent OncLive Peer Exchange, Dr. Gregory Vidal partnered with a panel of breast oncology experts to discuss the standard-of-care treatment approaches for early-stage HR-positive/HER2-negative breast cancer. Topics include: – Evolution of HER2-negative management – Updates in HR-positive treatment – Importance of genetic testing – Utilization of endocrine therapy – BRCA mutations and… Read more »
Dr. Jason Porter has partnered with OncLive to present a Lung Cancer State of the Science Summit! Academic & community-based physicians along with healthcare professionals are invited to attend this meeting on Thursday, May 11 in Nashville, TN. Attendees will expand their knowledge of novel treatment approaches and applying state-of-the-art treatment strategies. Click the link below to register… Read more »
Click here to view this full article on OncLive.com. The addition of immune checkpoint inhibitors to chemotherapy has led to durable responses and improved survival without increased toxicity in patients with small cell lung cancer (SCLC), according to David C. Portnoy, MD, FACP, who added that biomarkers of response to this approach and a… Read more »